Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Urothelial Cancer × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 49 Carcinoma, Renal Cell 44 Neoplasm Metastasis 21 Neoplasms 17 Kidney Neoplasms 16 Neuroendocrine Tumors 14 Lymphoma, Mantle-Cell 12 Carcinoma, Non-Small-Cell Lung 11 Recurrence 10 Prostatic Neoplasms 10 Hodgkin Disease 10 Tuberous Sclerosis 9 Stomach Neoplasms 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Lymphoma, Large B-Cell, Diffuse 9 Lymphoma 9 Glioblastoma 9 Colorectal Neoplasms 9 Brain Neoplasms 9 Lymphoma, Follicular 8 Leukemia, Lymphocytic, Chronic, B-Cell 8 Carcinoma 8 Waldenstrom Macroglobulinemia 7 Triple Negative Breast Neoplasms 7 Sarcoma 7 Multiple Myeloma 7 Lymphoma, B-Cell, Marginal Zone 7 Glioma 7 Central Nervous System Neoplasms 7 Carcinoma, Neuroendocrine 7

Interventions

niraparib 1 cabozantinib 1 avelumab 1 Sunitinib 1 Paclitaxel 1 Gemcitabine 1 Everolimus 1 Cisplatin 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01801137 2016-06-21

AFINIVEST

Hopital Foch

Phase 2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡